Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 10:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 32 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: methoxsalen Clear all
Recruiting Phase 2 Interventional

Photopheresis in Early-stage Mycosis Fungoides

NCT05680558
View directory record Official record
Conditions
Cutaneous T Cell Lymphoma, Mycosis Fungoides
Interventions
UVADEX® (methoxsalen) Sterile Solution in conjunction with the THERAKOS® CELLEX Photopheresis, THERAKOS® CELLEX photopheresis system
Drug · Device
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Sep 6, 2026, 10:12 AM EDT
Completed Phase 2 Interventional Results available

Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Transplant

NCT00639717
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
stem cell transplant, tacrolimus (standard GVHD prophylaxis), mycophenolate (standard GVHD prophylaxis), etanercept, methoxsalen
Procedure · Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
Not listed
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Sep 6, 2026, 10:12 AM EDT
Available No phase listed Expanded access

Single Patient Compassionate Use of X-PACT in Salvage Treatment of Prostate Cancer

NCT06836648
View directory record Official record
Conditions
Prostate Cancer
Interventions
X-PACT
Combination Product
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Sep 6, 2026, 10:12 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Rheumatoid Arthritis

NCT00221000
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Methoxsalen, Extracorporeal Photopheresis
Drug · Procedure
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
10
States / cities
Westminister, Maryland • Worchester, Massachusetts • Morristown, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2016 · Synced Sep 6, 2026, 10:12 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Crohn's Disease

NCT00221026
View directory record Official record
Conditions
Crohn's Disease
Interventions
Methoxsalen +ECP, Extracorporeal Photopheresis
Drug · Procedure
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
4
States / cities
Bethesda, Maryland • Chevy Chase, Maryland • Morristown, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2016 · Synced Sep 6, 2026, 10:12 AM EDT
Not listed Phase 2 Interventional

Chemotherapy and Photodynamic Therapy in Treating Patients With Cutaneous T-Cell Lymphoma

NCT00030589
View directory record Official record
Conditions
Lymphoma
Interventions
bexarotene, methoxsalen, UV light therapy
Drug · Procedure
Lead sponsor
Millennix
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
19
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Stanford, California + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Sep 6, 2026, 10:12 AM EDT
Completed Early Phase 1 Interventional Results available

Extracorporeal Photopheresis (ECP) With Methoxsalen for Chronic Graft Versus Host Disease (cGVHD)

NCT01380535
View directory record Official record
Conditions
Chronic Graft Versus Host Disease
Interventions
ECP Methoxsalen, Standard of Care
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years to 99 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
11
States / cities
Miami, Florida • Indianapolis, Indiana • New Orleans, Louisiana + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2020 · Synced Sep 6, 2026, 10:12 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Randomized Phase 2/3 Multi-Center Study of SM-88 in Participants With Metastatic Pancreatic Cancer

NCT03512756
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
SM-88 used with MPS (methoxsalen, phenytoin, sirolimus), Capecitabine, Gemcitabine, and 5-FU
Drug
Lead sponsor
Tyme, Inc
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
20
States / cities
Birmingham, Alabama • Duarte, California • Santa Monica, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Sep 6, 2026, 10:12 AM EDT
Active, not recruiting Phase 3 Interventional

Extracorporeal Photopheresis for Medicare Recipients of Lung Allografts

NCT02181257
View directory record Official record
Conditions
Bronchiolitis Obliterans Syndrome (BOS)
Interventions
Extracorporeal Photopheresis (ECP), No intervention in the SOC / Retrospective Chart review.
Combination Product · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
22
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Sep 6, 2026, 10:12 AM EDT
Completed Phase 4 Interventional

Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A

NCT00221039
View directory record Official record
Conditions
Cutaneous T Cell Lymphoma, Mycosis Fungoides
Interventions
Methoxsalen+ECP
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
7
States / cities
Chicago, Illinois • Boston, Massachusetts • Minneapolis, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Sep 6, 2026, 10:12 AM EDT
Completed Phase 3 Interventional

A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer

NCT04229004
View directory record Official record
Conditions
Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
Interventions
Gemcitabine combined with nab-paclitaxel, Dose -mFOLFIRINOX, Dose - Pamrevlumab combined with gemcitabine and nab-paclitaxel, Dose- Canakinumab and Spartalizumab combined with nab-paclitaxel and gemcitabine, Drug: Dose -SM-88
Drug
Lead sponsor
Pancreatic Cancer Action Network
Other
Eligibility
18 Years and older
Enrollment
502 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
25
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2025 · Synced Sep 6, 2026, 10:12 AM EDT
Terminated Phase 2 Interventional Results available

Biomarkers in Acute Graft-Versus-Host Disease and Extracorporeal Photopheresis Added to Investigator Chosen Therapies of Steroid Refractory Acute GVHD

NCT02322190
View directory record Official record
Conditions
Chronic Graft vs. Host Disease, Graft vs Host Disease, Graft-Versus-Host Disease
Interventions
Extracorporeal Photopheresis (ECP), Methoxsalen
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 11, 2020 · Synced Sep 6, 2026, 10:12 AM EDT
Completed Phase 1 Interventional

Extracorporeal Photopheresis to Maintain Symptoms Remission During Steroid Withdrawal in Patients With Steroid-Dependent Crohn's Disease

NCT00056355
View directory record Official record
Conditions
Crohn Disease
Interventions
UVADEX and UVAR XTS Photopheresis System
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 6, 2026, 10:12 AM EDT
Completed Phase 1Phase 2 Interventional

Study of the Efficacy, Safety, and Pharmacokinetics of SM88 in Patients With Prostate Cancer

NCT02796898
View directory record Official record
Conditions
Prostate Cancer, Rising Prostate Specific Antigen (PSA)
Interventions
SM88 (Cohort 1), SM88 (Cohort 2)
Drug
Lead sponsor
Tyme, Inc
Industry
Eligibility
18 Years and older · Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
5
States / cities
Lawrence, New Jersey • Garden City, New York • The Bronx, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2019 · Synced Sep 6, 2026, 10:12 AM EDT
Terminated Not applicable Interventional Results available

Open-Label Study to Evaluate the Efficacy of ECP in Secondary Progressive Multiple Sclerosis

NCT02296346
View directory record Official record
Conditions
Secondary Progressive Multiple Sclerosis
Interventions
SoluMedrol, Extracorporeal Photopheresis
Drug · Device
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 75 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Sep 6, 2026, 10:12 AM EDT
Completed Phase 2Phase 3 Interventional

Extracorporeal Photopheresis for Acute Graft Versus Host Disease

NCT00179855
View directory record Official record
Conditions
Graft Versus Host Disease, Cancer, Stem Cell Transplantation
Interventions
Extracorporeal Photopheresis
Procedure
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
Up to 30 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Sep 6, 2026, 10:12 AM EDT
Recruiting No phase listed Observational

Extracorporeal Photopheresis in Sezary Syndrome

NCT05157581
View directory record Official record
Conditions
Sezary Syndrome
Interventions
Extracorporeal photopheresis (ECP), Methoxsalen Injection
Device · Drug
Lead sponsor
Oleg E. Akilov, MD, PhD
Other
Eligibility
18 Years to 100 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
3
States / cities
Atlanta, Georgia • Baltimore, Maryland • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Sep 6, 2026, 10:12 AM EDT
Terminated Phase 3 Interventional

Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Acute Graft Versus-Host Disease

NCT00282503
View directory record Official record
Conditions
Acute Graft-versus-Host Disease
Interventions
Methoxsalen+ECP, Methylprednisolone, Ecp
Drug · Procedure
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
5
States / cities
Gainesville, Florida • Ann Arbor, Michigan • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2017 · Synced Sep 6, 2026, 10:12 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Photopheresis With UVADEX to Prevent Graft-versus-Host Disease

NCT00054600
View directory record Official record
Conditions
Graft-versus-Host Disease
Interventions
Methoxsalen, Extracorporeal Photopheresis
Drug · Procedure
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
6
States / cities
Gainesville, Florida • Chicago, Illinois • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2017 · Synced Sep 6, 2026, 10:12 AM EDT
Withdrawn Phase 2 Interventional

EPIC- Extracorporeal Photopheresis (ECP) for Immune-related Colitis

NCT06646016
View directory record Official record
Conditions
Immune-related Colitis
Interventions
Methoxsalen, Infliximab, Vedolizumab
Drug
Lead sponsor
Therakos LLC
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 25, 2025 · Synced Sep 6, 2026, 10:12 AM EDT
Terminated Phase 2 Interventional Results available

Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer

NCT04720664
View directory record Official record
Conditions
Breast Cancer, Metastatic Breast Cancer, Hormone Receptor Positive Breast Carcinoma
Interventions
SM-88
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 27, 2023 · Synced Sep 6, 2026, 10:12 AM EDT
Recruiting Phase 1 Interventional

X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma

NCT04389281
View directory record Official record
Conditions
Advanced Solid Tumor Cancer
Interventions
X-PACT
Combination Product
Lead sponsor
Immunolight, LLC
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Charlotte, North Carolina • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Sep 6, 2026, 10:12 AM EDT
Completed Phase 2 Interventional Results available

Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes

NCT00045305
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
Cyclosporine, Methotrexate, Photopheresis, Mycofenolate mofetil, Pentostatin, allogeneic bone marrow, peripheral blood stem cell, Total body irradiation
Drug · Procedure · Radiation
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 70 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
6
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Sep 6, 2026, 10:12 AM EDT
Terminated Not applicable Interventional Results available

Study of Pegylated Interferon-Alfa 2b in Combination With PUVA Therapy In CTCL

NCT00724061
View directory record Official record
Conditions
Lymphoma
Interventions
Pegylated interferon α-2b, Psoralens with ultraviolet light A, Narrowband-ultraviolet light B
Biological · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 120 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Sep 6, 2026, 10:12 AM EDT